RET and neoplasm: Tumor responses were assessable in eleven patients, with six patients achieving partial response, making selpercatinib a promising option for patients with RET fusion.373 In addition, in solid tumors with neurotrophin receptor kinase (NTRK) gene fusions, larotrectinib, and entrectinib are inhibiting NTRK and both showed benefits in basket trials, leading to their FDA approval.407–409 For example, entrectinib showed a partial response in two out of three patients with PDAC.407